S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Laser breakthrough could send stock soaring 2,467% (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Apple is expected to unveil sleek headset aimed at thrusting the masses into alternate realities
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
With oil prices slumping, OPEC+ producers weigh more production cuts
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Laser breakthrough could send stock soaring 2,467% (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Apple is expected to unveil sleek headset aimed at thrusting the masses into alternate realities
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
With oil prices slumping, OPEC+ producers weigh more production cuts
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Laser breakthrough could send stock soaring 2,467% (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Apple is expected to unveil sleek headset aimed at thrusting the masses into alternate realities
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
With oil prices slumping, OPEC+ producers weigh more production cuts
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
MarketBeat Week in Review – 5/29 - 6/2
Laser breakthrough could send stock soaring 2,467% (Ad)
Biden signs debt ceiling bill that pulls US back from brink of unprecedented default
Russia bans 'unfriendly' countries' journalists from showpiece economic gathering
“You need at least $100 of this asset – and it’s NOT gold” – Dr. Nomi Prin (Ad)
Slow start to New York's legal pot market leaves farmers holding the bag
Apple is expected to unveil sleek headset aimed at thrusting the masses into alternate realities
How A.I. Could Make Most 21st Century Diseases EXTINCT (Ad)
Oil tanker breaks down in Egypt's Suez Canal, briefly disrupting traffic in the global waterway
With oil prices slumping, OPEC+ producers weigh more production cuts
NASDAQ:PIRS

Pieris Pharmaceuticals (PIRS) Stock Forecast, Price & News

$0.90
+0.05 (+5.91%)
(As of 06/2/2023 ET)
Compare
Today's Range
$0.83
$0.90
50-Day Range
$0.72
$1.48
52-Week Range
$0.72
$2.12
Volume
127,882 shs
Average Volume
1.31 million shs
Market Capitalization
$73.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Pieris Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.24% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.57
Upright™ Environmental Score
News Sentiment
0.14mentions of Pieris Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$8,500 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($0.71) to ($0.67) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

484th out of 983 stocks

Pharmaceutical Preparations Industry

233rd out of 486 stocks


PIRS stock logo

About Pieris Pharmaceuticals (NASDAQ:PIRS) Stock

Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of Anticalin-based drugs. Its pipeline includes immuno-oncology, respiratory, and anemia and other disease areas. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

Receive PIRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pieris Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PIRS Stock News Headlines

15 A.I. Trading Opportunities a Day
Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.
“One-Stock Millionaire” IGNORES 99.9% of the Market
During the 2008 financial crisis, millionaire trader Jeff Clark stunned the world when he managed to double his readers’ money 26 TIMES… CNBC caught wind of this and asked Jeff to come on live TV to explain his secret.
See More Headlines

PIRS Price History

PIRS Company Calendar

Last Earnings
3/29/2023
Today
6/04/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PIRS
Employees
124
Year Founded
N/A

Profitability

Net Income
$-33,280,000.00
Net Margins
-245.45%
Pretax Margin
-245.45%

Debt

Sales & Book Value

Annual Sales
$16.85 million
Book Value
$0.19 per share

Miscellaneous

Free Float
76,032,000
Market Cap
$73.45 million
Optionable
Optionable
Beta
1.08

Key Executives

  • Stephen S. Yoder
    President, Chief Executive Officer & Director
  • Thomas Bures
    Senior VP, Chief Financial & Accounting Officer
  • Kayti Aviano
    Vice President-Clinical Operations
  • Hitto Kaufmann
    Chief Scientific Officer & Senior Vice President
  • Shane OlwillShane Olwill
    Chief Development Officer & Senior Vice President













PIRS Stock - Frequently Asked Questions

How have PIRS shares performed in 2023?

Pieris Pharmaceuticals' stock was trading at $1.04 at the beginning of the year. Since then, PIRS stock has decreased by 13.9% and is now trading at $0.8955.
View the best growth stocks for 2023 here
.

When is Pieris Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our PIRS earnings forecast
.

How were Pieris Pharmaceuticals' earnings last quarter?

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) released its quarterly earnings data on Wednesday, March, 29th. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.02. The biotechnology company earned $5.85 million during the quarter, compared to analyst estimates of $6.51 million. Pieris Pharmaceuticals had a negative net margin of 245.45% and a negative trailing twelve-month return on equity of 133.94%.

What other stocks do shareholders of Pieris Pharmaceuticals own?
What is Pieris Pharmaceuticals' stock symbol?

Pieris Pharmaceuticals trades on the NASDAQ under the ticker symbol "PIRS."

Who are Pieris Pharmaceuticals' major shareholders?

Pieris Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.63%), Platinum Investment Management Ltd. (1.31%), Acadian Asset Management LLC (0.85%), Renaissance Technologies LLC (0.52%), Candriam S.C.A. (0.47%) and Affinity Asset Advisors LLC (0.37%). Insiders that own company stock include Aquilo Capital Management, Llc, Christopher P Kiritsy, Shane Olwill and Tim Demuth.
View institutional ownership trends
.

How do I buy shares of Pieris Pharmaceuticals?

Shares of PIRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pieris Pharmaceuticals' stock price today?

One share of PIRS stock can currently be purchased for approximately $0.90.

How much money does Pieris Pharmaceuticals make?

Pieris Pharmaceuticals (NASDAQ:PIRS) has a market capitalization of $73.45 million and generates $16.85 million in revenue each year. The biotechnology company earns $-33,280,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

How many employees does Pieris Pharmaceuticals have?

The company employs 124 workers across the globe.

How can I contact Pieris Pharmaceuticals?

Pieris Pharmaceuticals' mailing address is 255 State Street 9th Floor, Boston MA, 02109. The official website for the company is www.pieris.com. The biotechnology company can be reached via phone at (857) 246-8998, via email at kelman@pieris.com, or via fax at 49-8161-141-1444.

This page (NASDAQ:PIRS) was last updated on 6/4/2023 by MarketBeat.com Staff

My Account -